Abstract
Arterial thrombosis (manifested as myocardial infarction, ischaemic stroke, or peripheral occlusive artery disease) and venous thrombosis (main clinical presentations include deep vein thrombosis and pulmonary embolism) represent major health problems that are associated with high rates of morbidity and mortality, particularly in Western societies. Several lines of evidence point to a role of novel hemostatic genetic risk factors in influencing thrombotic risk. In fact, it is becoming increasingly clear that the analysis of genetic risk factors and plasmatic factors, together with private life style and environmental factors may contribute significantly to our understanding of the genetic predisposition to vascular thrombosis. The most significant breakthrough was the confirmation of the notion that inherited hypercoagulable conditions are present in a large proportion of patients with venous thromboembolism. These include mutations in the genes encoding antithrombin, protein C, protein S, factor V, and prothrombin. Moreover, plasmatic risk indicators like hyperhomocysteinemia and elevated concentrations of factors II, VIII, IX, XI and fibrinogen have also been documented. Plasma levels of proteins of the hemostatic system also predict the onset and outcome of arterial thrombosis. Several studies examined the relationship between genetic markers of the hemostatic system (platelet receptors, endothelial receptors, anticoagulant proteins, coagulation factors and proteins of the fibrinolytic system) and arterial disease. The results from these studies are frequently conflicting and often are not concordant with plasmatic studies. Therefore, large prospective studies remain needed in order to evaluate the significance of hemostatic plasma levels and gene variations in arterial thrombotic diseases.
Keywords: Genetic Variations, Hemostatic System, Risk Factors, Arterial Thrombotic Disease, platelet, fibrinolytic system
Current Genomics
Title: Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Volume: 4 Issue: 4
Author(s): R. F. Franco, M. D. Trip and P. H. Reitsma
Affiliation:
Keywords: Genetic Variations, Hemostatic System, Risk Factors, Arterial Thrombotic Disease, platelet, fibrinolytic system
Abstract: Arterial thrombosis (manifested as myocardial infarction, ischaemic stroke, or peripheral occlusive artery disease) and venous thrombosis (main clinical presentations include deep vein thrombosis and pulmonary embolism) represent major health problems that are associated with high rates of morbidity and mortality, particularly in Western societies. Several lines of evidence point to a role of novel hemostatic genetic risk factors in influencing thrombotic risk. In fact, it is becoming increasingly clear that the analysis of genetic risk factors and plasmatic factors, together with private life style and environmental factors may contribute significantly to our understanding of the genetic predisposition to vascular thrombosis. The most significant breakthrough was the confirmation of the notion that inherited hypercoagulable conditions are present in a large proportion of patients with venous thromboembolism. These include mutations in the genes encoding antithrombin, protein C, protein S, factor V, and prothrombin. Moreover, plasmatic risk indicators like hyperhomocysteinemia and elevated concentrations of factors II, VIII, IX, XI and fibrinogen have also been documented. Plasma levels of proteins of the hemostatic system also predict the onset and outcome of arterial thrombosis. Several studies examined the relationship between genetic markers of the hemostatic system (platelet receptors, endothelial receptors, anticoagulant proteins, coagulation factors and proteins of the fibrinolytic system) and arterial disease. The results from these studies are frequently conflicting and often are not concordant with plasmatic studies. Therefore, large prospective studies remain needed in order to evaluate the significance of hemostatic plasma levels and gene variations in arterial thrombotic diseases.
Export Options
About this article
Cite this article as:
Franco F. R., Trip D. M. and Reitsma H. P., Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease, Current Genomics 2003; 4 (4) . https://dx.doi.org/10.2174/1389202033490349
DOI https://dx.doi.org/10.2174/1389202033490349 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design